China-Focused Biotech LianBio Drops in U.S. Trading Debut
(Bloomberg) -- Biotechnology firm LianBio fell 14% in its U.S. trading debut, sounding a cautionary note for companies operating primarily in China after a surge of such listings came to a halt in July.
LianBio's shares, which sold for $16 in its $325 million initial public offering, opened trading Monday at $15.50. The shares closed at $13.70 in New York, giving the company a market value of $1.44 billion. Accounting for employee stock options and warrants, the company has a fully diluted value of about $1.6 billion.
The biotech company was founded by New York private equity fund Perceptive Advisors, and the firm and its affiliates now control 50.5% of LianBio, according to its prospectus. LianBio, which lists headquarters in both Princeton, New Jersey, and Shanghai, does business primarily through subsidiaries in China.
U.S. IPOs by Chinese companies have nearly vanished since July, when Beijing announced a cybersecurity probe of Didi Global Inc. just days after its New York listing. The escalation of an apparent crackdown on China's corporates wiped about $1 trillion off the aggregate market value of its listed firms. The U.S. Securities and Exchange Commission has issued detailed queries to companies with links to China, and even Hong Kong-based companies with little to no presence in the mainland have been warning about risks.
Billionaire Richard Li's U.S. IPO of his Asian insurance group, FWD Group Holdings Ltd., stalled as regulators questioned whether the Chinese government could extend its authority to Hong Kong-based firms like FWD, Blooomberg News reported in October. In a revised filing Monday, FWD noted recent statements by the Chinese government and said there was no guarantee its operations wouldn't experience any material adverse impacts.
For More: China Is Said to Weigh Unprecedented Didi Penalty After IPO
Including Didi's $4.4 billion June 30 IPO, 46 companies based in China and Hong Kong raised more than $15 billion in the first half of the year in the U.S., according to data compiled by Bloomberg. Since then, only five such companies had raised $329 million combined before LianBio's IPO, the data show.
LianBio sold 20.3 million American depositary shares after marketing them for $15 to $17, according to a statement Sunday. Each ADS represents one ordinary share.
Limited Similarities
The similarities between LianBio's offering and Chinese companies like Didi are limited. The biotech firm doesn't hold personally identifiable data on patients in China, nor does it have a variable interest entity in its corporate structure, according to the prospectus. VIEs create a foreign shell company outside of China and were widely used by issuers from the country until falling under close scrutiny by Beijing authorities amid stringent new rules on overseas listings.
Still, LianBio said in the first page of its prospectus that there are “significant legal and operational risks associated with having the majority of our operations in China,” including potential changes in the legal, political and economic policies of the Chinese government.
LianBio focuses on in-licensing assets for greater China and other Asian markets, according to its filings. It has a pipeline of nine assets in the areas of cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. The company posted almost $140 million in losses in 2020 and $162 million for the six months ended in June.
The offering was led by Goldman Sachs Group Inc., Jefferies Financial Group Inc. and Bank of America Corp. The shares are trading on the Nasdaq Global Market under the symbol LIAN.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.